Ascendis Pharma

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma creates technologies to transform medicine and enable treatments to reach those with rare and complex diseases across the globe.

Ascendis Pharma will be recognized as the leader in the development of transformative treatments for rare and complex diseases that provide superior therapeutic benefit with improved convenience and compliance.

In 2019, Ascendis Pharma received Orphan Drug Designation and Priority Review Status from the FDA for TransCon hGH, an investigational once-weekly, long-acting recombinant human growth hormone therapy. In 2020, they were also awarded the prestigious Frost & Sullivan Digital Health Ecosystem Enabler Award.